Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys

被引:0
|
作者
Shawn M. Flynn
Phillip M. Epperly
April T. Davenport
Gerta Cami-Kobeci
Stephen M. Husbands
Mei-Chuan Ko
Paul W. Czoty
机构
[1] Wake Forest School of Medicine,Department of Physiology and Pharmacology
[2] University of Bath,Department of Pharmacy and Pharmacology
来源
Neuropsychopharmacology | 2019年 / 44卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Alcohol use disorder (AUD) persists as a devastating public health problem; widely effective pharmacological treatments are needed. Evidence from rodent models suggests that stimulating brain receptors for the neuropeptide nociceptin/orphanin FQ (NOP) can decrease ethanol drinking. We characterized the effects of the mu opioid peptide (MOP) receptor agonist buprenorphine and the buprenorphine analog (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6 methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028), which stimulates MOP and NOP receptors, in a translational nonhuman primate model of AUD. Rhesus monkeys drank a 4% ethanol solution 6 h per day, 5 days per week via an operant behavioral panel in their home cages. To assess behavioral selectivity, monkeys responded via a photo-optic switch to earn food pellets. After characterizing the acute effects of BU08028 (0.001–0.01 mg/kg, i.m.) and buprenorphine (0.003–0.056 mg/kg, i.m.), the drugs were administered chronically using a model of pharmacotherapy assessment that incorporates clinical aspects of AUD and treatment. Acutely, both drugs decreased ethanol drinking at doses that did not affect food-maintained responding. During chronic treatment, effects of BU08028 and buprenorphine were maintained for several weeks without development of tolerance or emergence of adverse effects. BU08028 was ~0.5 and 1.0 log units more potent in acute and chronic studies, respectively. The selective NOP receptor agonist SCH 221510 also selectively decreased ethanol intakes when given acutely (0.03–1.0 mg/kg, i.m.), whereas the MOP antagonist naltrexone (1.7–5.6 mg/kg, i.m.) decreased both ethanol intake and food pellets delivered. These data demonstrate that bifunctional MOP/NOP agonists, which may have therapeutic advantages to MOP-selective drugs, can decrease alcohol drinking in nonhuman primates.
引用
收藏
页码:1476 / 1484
页数:8
相关论文
共 50 条
  • [1] Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys
    Flynn, Shawn M.
    Epperly, Phillip M.
    Davenport, April T.
    Cami-Kobeci, Gerta
    Husbands, Stephen M.
    Ko, Mei-Chuan
    Czoty, Paul W.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2019, 44 (08) : 1476 - 1484
  • [2] Effects of BU08028, a Mixed Mu Opioid Receptor and Nociceptin/Orphanin FQ Peptide (NOP) Receptor Agonist, on Alcohol Drinking in Rhesus Monkeys
    Czoty, Paul
    Epperly, Phillip
    Davenport, April
    Ko, Mei-Chuan
    Husbands, Stephen
    Flynn, Shawn
    [J]. NEUROPSYCHOPHARMACOLOGY, 2017, 42 : S630 - S630
  • [3] DECREASES IN ETHANOL CONSUMPTION PRODUCED BY BIFUNCTIONAL MU OPIOID, NOCICEPTIN/ORPHANIN FQ PEPTIDE (NOP) RECEPTOR AGONISTS IN MONKEYS
    Czoty, P. W.
    Epperly, P. M.
    Davenport, A. T.
    Ko, M. C.
    Husbands, S. M.
    Flynn, S. M.
    [J]. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2018, 42 : 147A - 147A
  • [4] NOCICEPTIN/ORPHANIN FQ OPIOID PEPTIDE (NOP) RECEPTOR EXPRESSION IN PACHYONYCHIA CONGENITA (PC)
    Pan, B.
    Schroeder, W.
    Jostock, R.
    Schwartz, M.
    Polydefkis, M.
    [J]. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2017, 22 (03) : 353 - 353
  • [5] Behavioral Effects of a Synthetic Agonist Selective for Nociceptin/Orphanin FQ Peptide Receptors in Monkeys
    Ko, Mei-Chuan
    Woods, James H.
    Fantegrossi, William E.
    Galuska, Chad M.
    Wichmann, Juergen
    Prinssen, Eric P.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2009, 34 (09) : 2088 - 2096
  • [6] Behavioral Effects of a Synthetic Agonist Selective for Nociceptin/Orphanin FQ Peptide Receptors in Monkeys
    Mei-Chuan Ko
    James H Woods
    William E Fantegrossi
    Chad M Galuska
    Jürgen Wichmann
    Eric P Prinssen
    [J]. Neuropsychopharmacology, 2009, 34 : 2088 - 2096
  • [7] Brain and whole-body imaging in rhesus monkeys of 11C-NOP-1A, a promising PET radioligand for nociceptin/orphanin FQ peptide receptors
    Kimura, Yasuyuki
    Fujita, Masahiro
    Lohith, Talakad
    Zoghbi, Sami
    Tauscher, Johannes
    Chen, Zhaogen
    Pedregal, Concepcion
    Barth, Vanessa
    Pike, Victor
    Innis, Robert
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [8] Brain and Whole-Body Imaging in Rhesus Monkeys of 11C-NOP-1A, a Promising PET Radioligand for Nociceptin/Orphanin FQ Peptide Receptors
    Kimura, Yasuyuki
    Fujita, Masahiro
    Hong, Jinsoo
    Lohith, Talakad G.
    Gladding, Robert L.
    Zoghbi, Sami S.
    Tauscher, Johannes A.
    Goebl, Nancy
    Rash, Karen S.
    Chen, Zhaogen
    Pedregal, Concepcion
    Barth, Vanessa N.
    Pike, Victor W.
    Innis, Robert B.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (10) : 1638 - 1645
  • [9] Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system
    Ciccocioppo, Roberto
    Economidou, Daina
    Rimondini, Roberto
    Sommer, Wolfgang
    Massi, Maurizio
    Heilig, Markus
    [J]. BIOLOGICAL PSYCHIATRY, 2007, 61 (01) : 4 - 12
  • [10] Role of nociceptin/orphanin FQ and nociceptin opioid peptide receptor in depression and antidepressant effects of nociceptin opioid peptide receptor antagonists
    Park, Jong Yung
    Chae, Suji
    Kim, Chang Seop
    Kim, Yoon Jae
    Yi, Hyun Joo
    Han, Eunjoo
    Joo, Youngshin
    Hong, Surim
    Yun, Jae Won
    Kim, Hyojung
    Shin, Kyung Ho
    [J]. KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2019, 23 (06): : 427 - 448